AsclepiX Therapeutics, Inc. — Form D

AsclepiX Therapeutics, Inc. of Bethesda, MD, a company, filed a Form D exempt-offering notice with the SEC on 2024-04-26. The offering totals $12.5M, of which $10.0M was reported sold. Industry: Biotechnology.

Offering

Issuer

Officers, directors & promoters (25)

NameRoleLocation
Steven AltschulerDirectorWATERTOWN, MA
Ben AskewDirectorBethesda, MD
Josh BarerDirectorBethesda, MD
Chris GarabedianDirectorSan Francisco, CA
Jordan GreenDirectorBethesda, MD
Sapna SrivastavaDirectorBethesda, MD
Robert DempseyExecutive OfficerBethesda, MD
Niranjan PandeyExecutive OfficerBethesda, MD
Aleksander PopelExecutive OfficerBethesda, MD
Amir ShojaeiExecutive OfficerBethesda, MD
Jill TierneyExecutive OfficerBethesda, MD
Jordan J GreenDirectorPorte Vedra Beach, FL
Jordan J GreenExecutive OfficerPorte Vedra Beach, FL
Joshua BarerDirectorRochester, MI
Sapna S SrivastavaDirectorBaltimore, MD
Aleksander S Popel, PhDDirectorBaltimore, MD
Aleksander S Popel, PhDExecutive OfficerBaltimore, MD
Kevin S Slawin, MDDirectorBaltimore, MD
Kevin S Slawin, MDExecutive OfficerBaltimore, MD
Steven S Altschuler, MDDirectorBaltimore, MD
Joshua S BarerDirectorBaltimore, MD
Wendy PerrowDirectorBaltimore, MD
Wendy PerrowExecutive OfficerBaltimore, MD
Aleksander Popel, PhDDirectorBaltimore, MD
Kevin Slawin, MDDirectorBaltimore, MD

Other filings by this issuer (4)

FiledFormOfferingSold
2020-06-11D$35.0M$10.0M
2019-06-17D/A$10.0M$7.7M
2018-10-25D$7.5M$3.9M
2017-02-09D$1.0M$175K

More